Skip to main content

Table 4 Base model ICER

From: An economic model of long-term use of celecoxib in patients with osteoarthritis

  QALYs Costs ICER
nsNSAID 10.1678 $10,096  
Celecoxib 10.2982 $14,151  
Net incremental 0.1304 $4,055 $31,097
  1. ICER, incremental cost-effective ratio; QALY, quality-adjusted life year; nsNSAID, nonselective nonsteroidal anti-inflammatory drugs.